Determining agreement between immunohistochemistry and RT-qPCR for standard biomarkers in breast cancer: Validation on GEICAM 9906 clinical trial.

Gene expression profiling and expanded immunohistochemistry tests to guide the use of adjuvant chemotherapy in breast cancer management: a systematic review and cost-effectiveness analysis

“…This included two full peer-reviewed papers, 115,116 three meeting abstracts [117][118][119][120] and an unpublished manuscript provided by the manufacturer. 121 The design and patient characteristics of the six included studies are provided in Tables 16 and 17 respectively.…”

“…The methodological quality of the six included studies (seven citations) [115][116][117][118][119][120][121] is summarised in Figure 5 (further details are provided in Appendix 11). Of these, two studies performed well, 117,121 receiving a positive assessment for at least 17 out of 21 methodological quality items.…”

“…Using the same data reported by Bernard et al 119 for a cohort of 793 LN+ tumour samples, Martin et al 120 (AIC information has been removed). The Assessment of clinical effectiveness quality of this report was judged as low.…”

“…Analytical validity of PAM50 Two abstracts 118,119 reported data on analytical validity, both rated as low quality. One 118 employed a relatively small sample (n = 171) whereas the other 119 was based on a much larger sample (n = 793).…”

“…One 118 employed a relatively small sample (n = 171) whereas the other 119 was based on a much larger sample (n = 793). These studies provide a comparison of PAM50 against standard IHC measurements.…”